Skip to content
  • + 33 (0) 1 55 26 82 16
  • contact@cardiawave.com
  • 3-5 rue Jules Guesde, Bat B, 92300 Levallois-Perret, France
  • + 33 (0) 1 55 26 82 16
  • contact@cardiawave.com
  • 3-5 rue Jules Guesde, Bat B, 92300 Levallois-Perret, France

Search

  • Home
  • About Us
    • Cardiawave
    • Mission and values
    • The Team
    • Careers
  • Aortic Stenosis
    • Unmet Medical Need
    • Current Treatment
  • Health Professionals
    • Our device: Valvosoft® 
    • Scientific Publications
    • Congresses
  • News
    • News
    • Press releases
  • Contact
About Us

🔊 New Interview – Inside Cardiawave’s Journey with the EIC Scaling Club🎙️ Cardiawave’s presentation at LSI 2025

Jan 13, 2026 HeleneCardiawave 0
Events

Cardiawave at JESFC 2026!

Jan 8, 2026 HeleneCardiawave 0
Press Release

VALVOSOFT®, the first non-invasive treatment for severe Symptomatic Aortic Stenosis (sSAS) from Cardiawave receives CE Marking

Dec 4, 2025 HeleneCardiawave 0
Press Release

VALVOSOFT®, le premier traitement non invasif de la Sténose Aortique Sévère symptomatique (sSAS) développé par Cardiawave, obtient le marquage CE

Dec 4, 2025 HeleneCardiawave 0
Events

📢 Cardiawave’s Valvosoft® to be presented at PCR London Valves 2025!

Nov 6, 2025 HeleneCardiawave 0
Press Release

Cardiawave renforce son leadership avec la nomination de Jonathan Freeman, Président du CA

Oct 30, 2025 HeleneCardiawave 0

Blog

Clinical Studies

First patient suffering from severe symptomatic Aortic Stenosis treated with our Non-Invasive Ultrasound Therapy at CHU Lille

Sep 29, 2022
READ MORE
About Us

Cardiawave, lauréate concours INov 2022

Sep 28, 2022
READ MORE
Events

TCT 2022

Sep 16, 2022
READ MORE
Aortic Stenosis

Rétrécissement de la valve aortique, un traitement par ultrasons

Jul 20, 2022
READ MORE
Aortic Stenosis

Sténose aortique : la technologie à ultrasons qui pourrait changer la donne

Jun 22, 2022
READ MORE
Events

VIVATECH 2022

Jun 22, 2022
READ MORE
650x450-press-release2
Press Release

Cardiawave confirms the safety of Valvosoft®, its non-invasive ultrasound treatment for aortic stenosis.

Jun 14, 2022
READ MORE
650x450-press-release2
Press Release

Cardiawave announces the authorization by the French National Agency for the Safety of Medicines and Health Products (ANSM) to proceed with a new clinical study in France.

May 2, 2022
READ MORE
650x450-press-release2
Press Release

Cardiawave announces the success of its clinical trial to treat aortic stenosis.

Mar 22, 2022
READ MORE
Corporate News

WE HAVE A NEW WEBSITE!

Dec 2, 2021
READ MORE

Posts pagination

PrevPrevious page Page 1 … Page 14 Page 15 Page 16 … Page 21 NextNext page

Categories

  • About Us
  • Aortic Stenosis
  • Careers
  • Clinical Studies
  • Corporate News
  • Events
  • Other news
  • Press Release
  • Scientific Publications

Featured Posts

About Us

🔊 New Interview – Inside Cardiawave’s Journey with the EIC Scaling Club🎙️ Cardiawave’s presentation at LSI 2025

Jan 13, 2026 HeleneCardiawave 0
Events

Cardiawave at JESFC 2026!

Jan 8, 2026 HeleneCardiawave 0
Press Release

VALVOSOFT®, the first non-invasive treatment for severe Symptomatic Aortic Stenosis (sSAS) from Cardiawave receives CE Marking

Dec 4, 2025 HeleneCardiawave 0
Press Release

VALVOSOFT®, le premier traitement non invasif de la Sténose Aortique Sévère symptomatique (sSAS) développé par Cardiawave, obtient le marquage CE

Dec 4, 2025 HeleneCardiawave 0
Events

📢 Cardiawave’s Valvosoft® to be presented at PCR London Valves 2025!

Nov 6, 2025 HeleneCardiawave 0
Press Release

Cardiawave renforce son leadership avec la nomination de Jonathan Freeman, Président du CA

Oct 30, 2025 HeleneCardiawave 0

l Latest news

  • 🔊 New Interview – Inside Cardiawave’s Journey with the EIC Scaling Club🎙️ Cardiawave’s presentation at LSI 2025
  • Cardiawave at JESFC 2026!

l Our social networks

  • LinkedIn
  • Twitter

l Contact Us

3-5 rue Jules Guesde, Bat B, 92300 Levallois-Perret, France
+ 33 (0) 1 55 26 82 16
contact@cardiawave.com

Copyright © Cardiawave l February 5th 2026
  • Legal Mentions